Status:
RECRUITING
SEQUENTIAL PROFILING OF TUMOR-DERIVED CIRCULATING CELL-FREE DNA (ctDNA) IN ADVANCED OVARIAN CANCER PATIENTS
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18-80 years
Phase:
NA
Brief Summary
Ovarian cancer (OC) is the third most common gynaecologic cancer worldwide and has the highest mortality rate among gynaecologic cancers. Despite the advances in cytoreductive surgery and frontline ch...
Eligibility Criteria
Inclusion
- Newly diagnosed suspicious International Federation of Gynecology and Obstetrics (FIGO) stage III A or greater ovarian, fallopian tube, or primary peritoneal cancer
- Age between 18 and 80 years
- Estimated life expectancy of at least 4 weeks 4. Signed informed consent
Exclusion
- Any previous cancer in the last 5 years
- Previous chemotherapy or target treatments 3. Diagnosis of synchronous tumors
- Pregnancy or breastfeeding
- Missed informed consent
Key Trial Info
Start Date :
December 19 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06071286
Start Date
December 19 2023
End Date
October 30 2026
Last Update
February 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy